International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2021   Volume 11   Issue 4

Optimization of Lamivudine Solid Dispersions by Central Composite Design
Download PDF


, , , , ,
Citation
Vancouver
Ahad HA, Chinthaginjala H, Bitraganti SR, Dasari RR, Musa GBM, Jyothi VN. Optimization of Lamivudine Solid Dispersions by Central Composite Design. Int J Pharm Phytopharmacol Res. 2021;11(4):18-23. https://doi.org/10.51847/1KVQAZGWqU
APA
Ahad, H. A., Chinthaginjala, H., Bitraganti, S. R., Dasari, R. R., Musa, G. B. M., & Jyothi, V. N. (2021). Optimization of Lamivudine Solid Dispersions by Central Composite Design. International Journal of Pharmaceutical And Phytopharmacological Research, 11(4), 18-23. https://doi.org/10.51847/1KVQAZGWqU
Download citation:   EndNote   RIS
Article Link:
Abstract

Lamivudine (LVD) is in BCS class II with the issue of minimal oral bioavailability. This issue can be improvised by complexing LVD with polyethylene glycol-4000 (PEG-4000) and Pluronic F-68 (PF-68) by formulation design. The attempt optimized LVD tablets through central composite design (CCD). LVD tablets will be with > 95% dissolution after 30 minitues by employing PEG-4000 and PF-68. Nine LVD tablets were formulated by design and assessed for physicochemical constraints, disintegration time, and drug dissolution. The separate and mutual consequences of PEG-4000 and PF-68 on the disintegration time of LVD tablets are highly significant (P< 0.01). Intermittent levels of PEG-4000 and more levels of PF-68 gave less time for disintegration and a greater amount of drug dissolved at the end of 30 minitues. The study concludes that PF-68 decreases the disintegration time with its concentration and PEG-4000 concentration ingresses the drug release from the formulation. The study also discovered that the optimized LVD tablet with > 97.5% dissolution in 30 minitues could be formulated by employing PEG-4000 at 30 mg and PF-68 at 44.8 mg (F-7).

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

International Journal of Pharmaceutical and Phytopharmacological Research
© 2024 All rights reserved